BMY
Bristol-Myers SquibbPrices and gamma are point-in-time snapshots taken at the time shown. Dealer positioning is an assumption, not an observable: open interest shows that a contract exists, never which side a dealer holds. How dealer gamma is computed.
LIVE MARKET SNAPSHOT
| Call Wall | 65 |
| Put Wall | 62.5 |
| GEX Flip | 64 |
| Vol Trigger | 64 |
| Net GEX | $13.7M |
Cached snapshot as of 2026-09-16 09:10 UTC, live streaming data in the terminal.
BMY DEALER GAMMA BY STRIKE
Part of the SquawkFlow GEX Calculator: gamma by strike for any US stock. Compare with SPX GEX.
Net gamma exposure at each strike near BMY's spot price, signed from the dealer perspective, calls positive, puts negative. Green strikes are where hedging tends to dampen moves; red is where it tends to amplify them. Dealer positioning is an assumption rather than an observable, so treat these as a map of where hedging pressure concentrates, not a forecast.
Unit: USD of dealer gamma per 1 percent move in spot. A window of the BMY option chain, not the whole book: the 30 strikes nearest spot out of 52 seen, 874 contract rows spanning 17 expirations. Gamma is taken as the chain publishes it per contract; nothing here is re-priced. Crossed with the open interest carried on that chain.
New to these levels? Start with the call wall and put wall, or the zero gamma level where the sign of dealer hedging flips.
| Strike | Net GEX | Call GEX | Put GEX | Concentration |
|---|---|---|---|---|
| 52 | $0 | $0 | $0 | |
| 52.5 | -$347.3K | $190.7K | -$538.0K | |
| 53 | $0 | $0 | $0 | |
| 54 | $0 | $0 | $0 | |
| 55 | -$1.9M | $0 | -$1.9M | |
| 56 | $0 | $0 | $0 | |
| 57 | -$6.5K | $0 | -$6.5K | |
| 57.5 | -$1.6M | $15.5K | -$1.7M | |
| 58 | -$4.8K | $0 | -$4.8K | |
| 59 | -$2.9K | $0 | -$2.9K | |
| 60 | -$436.7K | $5.5M | -$6.0M | |
| 61 | -$13.4K | $0 | -$13.4K | |
| 62 | -$170.0K | $16.5K | -$186.5K | |
| 62.5PUT WALL | -$3.2M | $7.0M | -$10.2M | |
| 63 | -$175.8K | $168.1K | -$344.0K | |
| 64SPOTGEX FLIP | $265.1K | $292.9K | -$27.9K | |
| 65CALL WALL | $8.7M | $13.1M | -$4.4M | |
| 66 | $223.0K | $381.3K | -$158.4K | |
| 67 | $265.6K | $265.6K | $0 | |
| 67.5 | $4.1M | $4.2M | -$61.2K | |
| 68 | $279.4K | $281.9K | -$2.5K | |
| 69 | $78.1K | $78.1K | $0 | |
| 70 | $5.2M | $5.2M | -$14.2K | |
| 71 | $0 | $0 | $0 | |
| 72 | $196 | $196 | $0 | |
| 72.5 | $580.0K | $580.0K | $0 | |
| 73 | $587 | $587 | $0 | |
| 74 | $0 | $0 | $0 | |
| 75 | $1.7M | $1.7M | $0 | |
| 76 | $0 | $0 | $0 |
These levels were captured September 16, 2026 from the open interest carried on the option chain. New levels post before each market open. Today's SPX gamma levels.
ABOUT BMY
Bristol-Myers Squibb is a global biopharma company with strengths in oncology (Opdivo, Revlimid), cardiovascular (Eliquis), and immunology. The company acquired Celgene in 2019 for $74 billion and has been actively managing patent cliffs through pipeline development and bolt-on acquisitions.
WHY TRACK BMY ON SQUAWKFLOW
BMY put/call ratios are closely watched as the company navigates major patent expirations. Options flow around Eliquis and Revlimid loss-of-exclusivity dates signals institutional views on revenue replacement.
BMY DATA ON SQUAWKFLOW
Options Flow
BMY options flow, unusual activity, and volume concentrations from the session chain
Latest Snapshot
Last BMY price, change, volume, and the current dealer-gamma regime
GEX Dashboard
BMY gamma exposure levels, call/put walls, and GEX flip
AI Narration
AI-powered analysis of BMY market microstructure in real time
News Sentiment
BMY news with AI sentiment scoring and impact analysis
Sector Context
Healthcare sector rotation and relative strength vs peers
Track BMY in the Terminal
Options flow, per-strike dealer gamma, key levels, and AI narration, free.
Open Terminal →LEARN MORE
A thorough explanation of implied volatility, how it is calculated, what it means, and how to use it in trading.
Max Pain Theory in Options: Should You Trust It?Understanding the max pain theory, how to calculate it, its track record, and practical ways to use it in your trading.